Depression sits at the intersection of obesity, GLP-1 therapy, and the broader social context of weight-loss medications. The evidence base is moving in two directions at once: real-world signals suggesting GLP-1 use reduces depression and anxiety risk, and patient-level data showing the social stigma of medication-driven weight loss adds psychological friction that diet-and-exercise loss does not.
Covered here: the ECO 2026 real-world analysis of 34,000+ women showing 25% lower depression risk on Wegovy versus menopausal hormone therapy alone (May 12); the March 2026 ScienceDaily writeup on Ozempic-linked lower depression, anxiety, and addiction risk; the Rice University May 5 study (International Journal of Obesity) documenting heightened social stigma around GLP-1-driven weight loss; and the broader patient-disclosure literature around peptide therapy use.
Stories here cover trial-based signals, real-world cohort findings, and the social-context research shaping how GLP-1 prescribers and patients navigate mental-health side effects and stigma. See #glp-1, #wegovy, and #stigma.
A second post-hoc analysis of STEP UP presented Tuesday found Wegovy 7.2 mg delivered consistent weight loss across reproductive life stages: 22.6% premenopausal, 19.7% perimenopausal, 19.8% postmenopausal, with 41.4% of premenopausal women hitting ≥25% loss. Waist-circumference reductions: 17.5%, 15.6%, 15.3% respectively. Separately, a real-world analysis of 34,000+ women showed that those taking Wegovy had a 42-45% lower migraine risk and a 25% lower depression risk starting six months in versus those on menopausal hormone therapy alone. The real-world data lands as observational signals that warrant prospective study — not as proof of causation — but reinforces the cardiovascular and quality-of-life narrative for the women's-health subgroup.
A 16-week randomized, double-blind trial of oral semaglutide in 72 adults with major depressive disorder found no improvement in executive function vs placebo. However, secondary analyses showed semaglutide improved global cognition and produced clinically significant weight loss, suggesting potential but unclear neuropsychiatric benefit.
Large-scale study from University of Eastern Finland and Karolinska Institutet found GLP-1 medications associated with 42% drop in psychiatric hospital visits, 44% lower depression risk, and 47% reduced substance use disorders.